Literature DB >> 2908020

Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users.

S J Peroutka1, H Newman, H Harris.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy) is a serotonergic neurotoxin in laboratory animals that has been used for recreational purposes by humans. The subjective effects of this drug were determined in recreational users at a university campus. Of individuals who had admitted to using MDMA recreationally, 100 of 143 agreed to complete a detailed questionnaire concerning the subjective effects of this Schedule I compound. The most common effect of MDMA was a heightened sense of "closeness" with other people (90% of subjects). Tachycardia, dry mouth, bruxism and/or trismus were reported by the majority of users. These effects probably result from the amphetaminelike properties of the drug. Visual hallucinations were reported by 20% of users. Untoward side effects were most common on the day following the use of MDMA, with complaints of muscle aches, fatiguability, depression, and difficulty concentrating noted by 21% to 36% of subjects. Sixty-seven percent of frequent users of the drug (six or more separate doses) reported that the "positive" effects of the drug decreased with successive doses while the "negative" effects increased. Although these observations should be considered preliminary, they represent the first documentation of the subjective effects of MDMA in recreational users and confirm previous reports obtained from patients treated with this drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2908020

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  44 in total

1.  Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.

Authors:  A C Parrott; T Buchanan; T M Heffernan; A Scholey; J Ling; J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

2.  The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).

Authors:  A C Parrott; J Rodgers; T Buchanan; A B Scholey; T Heffernan; J Ling
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

3.  Ecstasy and the dance of death.

Authors:  J A Henry
Journal:  BMJ       Date:  1992-07-04

4.  Neurotoxicity of methamphetamine and methylenedioxymethamphetamine.

Authors:  L S Seiden; R Lew; J E Malberg
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

Review 5.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

6.  Ecstasy (MDMA) Alters Cardiac Gene Expression and DNA Methylation: Implications for Circadian Rhythm Dysfunction in the Heart.

Authors:  Christopher A Koczor; Ivan Ludlow; Robert S Hight; Zhe Jiao; Earl Fields; Tomika Ludaway; Rodney Russ; Rebecca A Torres; William Lewis
Journal:  Toxicol Sci       Date:  2015-08-06       Impact factor: 4.849

7.  5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats.

Authors:  J H Kehne; R A Padich; T C McCloskey; V L Taylor; C J Schmidt
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

8.  MDMA induced dopamine release in vivo: role of endogenous serotonin.

Authors:  S Koch; M P Galloway
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

9.  Chronic MDMA (ecstasy) use, cognition and mood.

Authors:  K McCardle; S Luebbers; J D Carter; R J Croft; C Stough
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

10.  Attenuation of ecstasy-induced neurotoxicity by N-acetylcysteine.

Authors:  Sara Soleimani Asl; Bita Saifi; Abolhasan Sakhaie; Somayeh Zargooshnia; Mehdi Mehdizadeh
Journal:  Metab Brain Dis       Date:  2014-08-06       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.